Skip to main content

Table 3 Sensitivity analysis results. RRs quantifying the familial aggregation of persistence and heritability of persistence based on sensitivity analysis sub-cohorts taken from the main cohort of Swedish early RA patients diagnosed 1999–2019, treated with MTX in monotherapy as their first prescribed DMARD and with a first-degree relative concordant for early RA and treatment with MTX in DMARD monotherapy; the first being a sub-cohort of only full siblings and the second being a sub-cohort within individuals included into SRQ during 2006-2018, where both early RA and first-line treatment with MTX in DMARD monotherapy were validated against NPR and PDR

From: Does persistence to methotrexate treatment in early rheumatoid arthritis have a familial component?

 

Full siblings

Validated against NPR and PDR

MTX persistence at 1 year

MTX persistence at 3 years

MTX persistence at 1 year

MTX persistence at 3 years

Persistent N = 97

Not persistent N = 54

Persistent N = 73

Not persistent N = 78

Persistent N = 142

Not persistent N = 58

Persistent N = 109

Not persistent N = 91

RR (95% CI)

1.12 (0.84–1.50)

1.67 (1.16–2.40)

1.07 (0.88–1.31)

1.26 (0.97–1.63)

h2 (95% CI)

0.40 (0a–0.90)

1.00a (0.65–1.00a)

0.23 (0.00a–0.73)

0.45 (0.05–0.84)

  1. DMARD disease-modifying anti-rheumatic drug, MTX methotrexate, NPR National Patient Register, PDR Prescribed Drug Register, RR relative risk, RA rheumatoid arthritis, SRQ Swedish Rheumatology Quality Register
  2. aTruncated confidence interval boundary